The Chinese NDRC fines two pharmaceutical companies for excessive pricing and refusal to deal (Zhejiang Second Pharma / Tianjin Handewei Pharmaceuticals)

Fels, Allan; Emch, Adrian; Ng, Wendy; Wang, Xiaoye

Previous article The US Democrats publish "A Better Deal" policy statement with proposals to change antitrust/competition enforcement Next article The Spanish High Court rules that the constitutional principle of the individual nature of penalties precludes a parent company from being held to be the perpetrator of anti-competitive practices on the market in the motor fuels market solely because of its shareholding in the capital of its subsidiary (Repsol)

31 Jul 2017

The Chinese NDRC fines two pharmaceutical companies for excessive pricing and refusal to deal (Zhejiang Second Pharma / Tianjin Handewei Pharmaceuticals)

KEYWORDS

Reference

Chinese NDRC, Zhejiang Second Pharma / Tianjin Handewei Pharmaceuticals, Press Release, 31 July 2017 (Chinese)

On 31 July 2017, the NDRC publicly announced its decision to sanction Zhejiang Second Pharma (an affiliate of a

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Authors

Allan Fels
University of Melbourne

Australia 103 contributions 28506 visits
Adrian Emch
Hogan Lovells (Beijing)

China 80 contributions 18798 visits
Wendy Ng
University of Melbourne

Australia 68 contributions 15474 visits
Xiaoye Wang
China Competition Bulletin (Beijing)

China 101 contributions 25455 visits

Quotation

Allan Fels, Adrian Emch, Wendy Ng, Xiaoye Wang, The Chinese NDRC fines two pharmaceutical companies for excessive pricing and refusal to deal (Zhejiang Second Pharma / Tianjin Handewei Pharmaceuticals), 31 July 2017, e-Competitions July 2017, Art. N° 88631

Visites 201